资讯

Sanofi’s (NASDAQ:SNY) Riliprubart Granted Orphan Frug Designation in Japan
Sanofi (NASDAQ:SNY) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 30, Sanofi (NASDAQ:SNY) announced that ...
FDA Grants Orphan Drug Designation To Sanofi’s (SNY) Riliprubart
Sanofi (NASDAQ:SNY) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 25, Sanofi (NASDAQ:SNY) ...
Insider Monkey4 天
FDA Grants Orphan Drug Designation To Sanofi’s (SNY) Riliprubart
On June 25, Sanofi (NASDAQ:SNY) announced that the FDA granted orphan drug designation to Riliprubart for treating antibody-mediated rejection in solid organ transplantation.
Pulmonology Advisor4 小时
June 2025 Recap: Drug Pipeline Updates
The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.
infomeddnews3 天
June 25, 2025 - Page 9 Of 9 - Medical Device News Magazine
Riliprubart Earns Orphan Drug Designation in the US for Antibody-mediated Rejection in Solid Organ Transplantation This designation reflects Sanofi’s commitment to addressing a critical unmet need in ...
2025 上半年，国内 31 款生物药新药进入 III 期临床
与去年上半年情况不同，今年第二大主要布局领域为感染性疾病，共有 9 款生物药新药首次进入 III 期，来自辉瑞、万泰生物、华兰生物等企业。从成分类别来看，除预防性疫苗以外，还涉及非抗体类融合蛋白、单抗。 已顺利完成的 GC101-2 型 IND 项目 I/II 期临床试验数据表明，接受 GC101 注射液治疗的 2 型 SMA 受试者已观察到积极且显著的疗效，多名受试者获得了运动里程碑的突破。